top 3 things drug companies should know when choosing a packaging partner for diabetes medications

The number of biologic drug products marketed with an injection device has approximately quadrupled over the last decade. The growth in these drug therapies has been driven by several factors including new, self-administered therapies for chronic conditions such as rheumatoid arthritis and autoimmune diseases. In addition, injectable therapy is now being considered as a treatment for more conditions, including asthma and cholesterol problems.

Graham Reynolds

VP & GM, Global Biologics

In recent years, there has been a shift in the pharmaceutical industry toward a Quality by Design (QbD) philosophy. To maximize a drug product’s safety and efficacy, pharmaceutical companies and their drug packaging and delivery partners are building new quality principles into the entire manufacturing process, from design and development to commercialization and administration. This scientific, risk-based QbD approach is fast becoming an essential strategy for bringing high-quality therapeutics to market quickly and efficiently.

Tibor Hlobik

Sr. Director, PFS, Marketing

Many of the newer biologic products being developed are for long-term administration in chronic disease conditions, including oncology, autoimmune disorders and high cholesterol. Historically, these biologics have been administered by costly intravenous (IV) injection in a hospital, clinic or doctor’s office.

West's Innovation and Technology Team

Join West&rsquo;s Graham Reynolds as he presents the keynote at Pharmapack North America.&nbsp; Graham will present, &ldquo;<em><strong>Understanding the regulations and safety concerns surrounding injectables to overcome inherent design challenges&rdquo; </strong>on </em>Wednesday, May 23, 2012 at 1:50 pm.&nbsp; The conference will be held at the Pennsylvania Convention Center, Philadelphia, PA on May 22-23.&nbsp;

Global Communications

When you think of injectable medication, a classic image may include a set of hands holding both a vial and a syringe to withdraw medication prior to injection. Advances in both drug products and self-injection options &ndash; including auto-injectors, pens and other self-injection devices &ndash; have helped to draw a new picture for injectable delivery.<br />

Royce Brockett

Director, Product Management, Prefillable Systems